Vivoryon Therapeutics (Netherlands) Probability of Future Stock Price Finishing Over 2.03
| VVY Stock | 1.99 0.03 1.49% |
Vivoryon |
Vivoryon Therapeutics Target Price Odds to finish over 2.03
The tendency of Vivoryon Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over 2.03 or more in 90 days |
| 1.99 | 90 days | 2.03 | about 86.67 |
Based on a normal probability distribution, the odds of Vivoryon Therapeutics to move over 2.03 or more in 90 days from now is about 86.67 (This Vivoryon Therapeutics NV probability density function shows the probability of Vivoryon Stock to fall within a particular range of prices over 90 days) . Probability of Vivoryon Therapeutics price to stay between its current price of 1.99 and 2.03 at the end of the 90-day period is nearly 4.2 .
Assuming the 90 days trading horizon Vivoryon Therapeutics has a beta of 0.87. This entails Vivoryon Therapeutics NV market returns are related to returns on the market. As the market goes up or down, Vivoryon Therapeutics is expected to follow. Additionally Vivoryon Therapeutics NV has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Vivoryon Therapeutics Price Density |
| Price |
Predictive Modules for Vivoryon Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Vivoryon Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Vivoryon Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Vivoryon Therapeutics is not an exception. The market had few large corrections towards the Vivoryon Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Vivoryon Therapeutics NV, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Vivoryon Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.13 | |
β | Beta against Dow Jones | 0.87 | |
σ | Overall volatility | 0.18 | |
Ir | Information ratio | -0.03 |
Vivoryon Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Vivoryon Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Vivoryon Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Vivoryon Therapeutics had very high historical volatility over the last 90 days | |
| Vivoryon Therapeutics may become a speculative penny stock | |
| Vivoryon Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 10.76 M. Net Loss for the year was (12.65 M) with profit before overhead, payroll, taxes, and interest of 9.2 M. | |
| Vivoryon Therapeutics generates negative cash flow from operations | |
| About 33.0% of the company outstanding shares are owned by insiders |
Vivoryon Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Vivoryon Stock often depends not only on the future outlook of the current and potential Vivoryon Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Vivoryon Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 22.1 M |
Vivoryon Therapeutics Technical Analysis
Vivoryon Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Vivoryon Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Vivoryon Therapeutics NV. In general, you should focus on analyzing Vivoryon Stock price patterns and their correlations with different microeconomic environments and drivers.
Vivoryon Therapeutics Predictive Forecast Models
Vivoryon Therapeutics' time-series forecasting models is one of many Vivoryon Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Vivoryon Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Vivoryon Therapeutics
Checking the ongoing alerts about Vivoryon Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Vivoryon Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Vivoryon Therapeutics had very high historical volatility over the last 90 days | |
| Vivoryon Therapeutics may become a speculative penny stock | |
| Vivoryon Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 10.76 M. Net Loss for the year was (12.65 M) with profit before overhead, payroll, taxes, and interest of 9.2 M. | |
| Vivoryon Therapeutics generates negative cash flow from operations | |
| About 33.0% of the company outstanding shares are owned by insiders |
Additional Tools for Vivoryon Stock Analysis
When running Vivoryon Therapeutics' price analysis, check to measure Vivoryon Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivoryon Therapeutics is operating at the current time. Most of Vivoryon Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivoryon Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vivoryon Therapeutics' price. Additionally, you may evaluate how the addition of Vivoryon Therapeutics to your portfolios can decrease your overall portfolio volatility.